CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)

Ad-RTS-hIL-12 (Ad) is a gene therapy candidate for intratumoral (IT) delivery that conditionally expresses IL-12 (IL-12) under the transcriptional control of orally administered veledimex (V) acting via the RheoSwitch Therapeutic System(â) gene switch. Increased PD-1 expression in samples of rGBM fo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Lukas, Rimas, Chiocca, E Antonio, Bush, Nancy Ann Oberheim, Landolfi, Joseph, Cavaliere, Robert, Yu, John, Kurz, Sylvia, Demars, Nathan, Buck, Jill, Hadar, Nira, Miao, John, Loewy, John, Wang, Yunxia, Gelb, Arnold, Cooper, Laurence
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2020
Soggetti:
Clinical Trials: Immunologic
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650356/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.162
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi